For how we live.
In the single-arm EPCORE NHL-2 cohort, adding epcoritamab to rituximab and lenalidomide produced responses in 95% of 41 untreated follicular lymphoma patients, with no control group to prove added benefit.
In the phase 3 BRUIN CLL-322 trial, adding pirtobrutinib to a fixed course of venetoclax and rituximab raised 24-month progression-free survival to 87% from 72% in previously treated disease.
In the head-to-head OVERLORD-MS trial, 92.2% on rituximab and 94.8% on ocrelizumab had no new MRI lesions from months 6 to 24, meeting the prespecified bar for noninferiority.